Posts Tagged: licenseable technologies

Biotechnology Focus’ December issue covers MaRS Innovation projects and partnerships

MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including: MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website. Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research. MaRS Innovation's ... Read more

Start-Up Snapshot: Flybits, OtoSim, ApneaDX, ScarX Therapeutics

Happy New Year. Here's a snapshot of some spin-off stories you may have missed over the holiday break: Flybits and Flybits Lite, the startup company's context-aware mobile technology that anyone can use, was mentioned in a Smithsonian.com article as one of six technologies changing the way the way humans live. ApneaDx was featured in a company profile post on the MaRS Blog: "ApneaDx: First we take Ontario, then we take the world." ScarX Therapeutics launched its website. OtoSim Inc. co-founder Dr. Vito ... Read more

MI Inventors Poon and Rahnama Pitch EMTech 2012 (Videos Online)

Being named to the MIT Technology Review's 35 Inventors Under 35 list is a prestigious honour, but one of its best perks is the subsequent invitation to attend the Emerging Technologies conference (EmTech). Joyce Poon and Hossein Rahnama, both researchers and inventors working with MaRS Innovation to license or spin-off technology projects, were named to the MIT Technology Review‘s prestigious 35 Inventors Under 35 list for 2012. They attended the EmTech 2012 from October 24 to 26 where they each made a three-minute ... Read more

We’ve refreshed our website: Beta version now live

Welcome to the beta version of the MaRS Innovation website. We have refreshed the site's design to make better use of its existing functionality while  showcasing our projects. The new design includes these additions and changes: (more…) Read more

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online). Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…) Read more

Video: Canadian International Council interviews Rafi Hofstein about commercializing Canadian technology

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, spoke to the Canadian International Council about the importance of protecting intellectual property as an important component in commercializing Canadian technologies. Here's an excerpt: Government could be extremely helpful if they created special funds dedicated to covering the costs of patent protection. (more…) Read more

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions. “From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ... Read more

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it - part of a growing trend of selling science to help shore up Canada's troubled health-care system. Tuesday's agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question. But the licensing deal with one of the world's biggest drug companies ... Read more

MaRS Innovation and Sunnybrook Health Sciences Centre Partner to Develop Four Exciting Medical Discoveries

TORONTO (March 23, 2010) — MaRS Innovation and Sunnybrook Health Sciences Centre have entered into their first set of agreements to collaboratively commercialize a novel therapeutic technology and three advances in medical imaging. These four technologies will impact diagnosis and care for epidemic chronic illnesses and have clear and broad commercial potential. MI will shepherd these opportunities through the next stages of the commercialization process. “We are coming out of the gate vigorously in identifying this group of Sunnybrook technologies as commercialization ... Read more

MaRS Innovation and CDRD Announce Strategic Collaboration

TORONTO, ON and VANCOUVER, BC (November 30, 2009) - MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries. “We are excited about our partnership with the CDRD as it provides an opportunity for the two organizations to augment each other’s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations’ ... Read more
Page 2 of 3123